Tech Company Financing Transactions
Accropeutics Funding Round
Accropeutics, based in Suzhou, Jiangsu, secured $12 million from Shenzhen Capital and Morningside Ventures.
Transaction Overview
Company Name
Announced On
3/14/2025
Transaction Type
Venture Equity
Amount
$12,000,000
Round
Series B
Investors
Shenzhen Capital (Lead Investor)
Proceeds Purpose
The company intends to use the funds to expand operations and its business reach.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Suzhou, Jiangsu, Undisclosed
China
Suzhou, Jiangsu, Undisclosed
China
Phone
Website
Email Address
Overview
Accropeutics has developed a robust portfolio of innovative compounds spanning from lead optimization to clinical trials. The company's RIPK1 inhibitor AC-003 has completed the Phase I clinical trial in China and the United States in August 2023 and achieved positive results, and the clinical trial for aGvHD patients is currently undergoing. The Company's RlPK2 inhibitor AC-101 has completed the Phase I clinical trial in Australia demonstrating an outstanding safety and PK/PD profile. AC-201, a selective TYK2/JAK1 inhibitor with "Pipeline-in-a-Product" potential for treating inflammatory and autoimmune diseases, has completed the Phase I trial in Australia and China, and is currently in Phase II clinical trial for patients with moderate to severe plaque psoriasis. The Company has multiple compounds in the PCC and preclinical research stages. The Company owns global rights of all its assets with more than 10 patents issued in major markets including the US, the EU, China, Japan, and Kor
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Xiaohu Zhang
Browse more venture capital transactions:
Prev: 3/14/2025: Cheersy venture capital transaction
Next: 3/14/2025: Seadronix venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs